Introduction & Objective: The increasing prevalence of diabetes in the US continues to drive a steady rise in healthcare resource utilization. The real-world impact of continuous glucose monitoring (CGM) on hospitalizations in a broad type 2 diabetes population is not completely understood. Methods: In this retrospective analysis, we used Optum's de-identified Market Clarity data of >79 million people to evaluate CGM use in 74,264 people with type 2 diabetes who were treated with non-insulin (NIT; n=25,788), basal insulin (BIT; n=25,292), and prandial insulin therapy (PIT; n=23,184). The primary outcomes were changes in all-cause hospitalizations (ACH), acute diabetes-related hospitalizations (ADH), and acute diabetes-related emergency room visits (ADER) during the 6- and 12-months post-index period. Results: ACH, ADH, and ADER were significantly reduced in the first 6 months (post-index) in all three groups: NIT (14%, 32%, 30%), BIT (25%, 57%, 37%), PIT (25%, 54%, 36%) respectively. (Figure 1) The reductions were sustained during 6-12 months in NIT (10%, 31%, 30%), BIT (23%, 56%, 34%), and PIT (19%, 49%, 36%) respectively (all p<0.0001). Conclusion: The use of CGM in real-world across different therapeutic regimes in people with type 2 diabetes was associated with significant reductions in all-cause hospitalizations, acute diabetes-related hospitalizations and ER visits. Disclosure S.K. Garg: Research Support; Eli Lilly and Company. Advisory Panel; Medtronic. Research Support; Medtronic. Advisory Panel; Novo Nordisk. Research Support; DarioHealth Corp., Dexcom, Inc., Diasome. Advisory Panel; Roche Diabetes Care. I.B. Hirsch: Advisory Panel; Abbott. Research Support; Dexcom, Inc. Advisory Panel; Roche Diabetes Care. Research Support; MannKind Corporation, Tandem Diabetes Care, Inc. Advisory Panel; embecta. Research Support; Tandem Diabetes Care, Inc. Advisory Panel; Vertex Pharmaceuticals Incorporated. E. Repetto: Employee; Roche Diabetes Care. J.K. Snell-Bergeon: None. B. Ulmer: Employee; Roche Diabetes Care. C. Perkins: Employee; Roche Diabetes Care. R.M. Bergenstal: Other Relationship; Abbott. Research Support; Arkray Marketing. Consultant; Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur. Other Relationship; Dexcom, Inc., Eli Lilly and Company. Consultant; embecta, Hygieia. Research Support; Insulet Corporation. Consultant; MannKind Corporation. Other Relationship; Medtronic, Novo Nordisk. Consultant; Onduo LLC, Roche Diabetes Care. Other Relationship; Sanofi. Research Support; Tandem Diabetes Care, Inc. Other Relationship; UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S. Funding Roche Diagnostics, Diabetes Care

中文翻译：

---

1927-LB：连续血糖监测的使用对 2 型糖尿病患者住院治疗的影响 — 真实世界分析


简介和目标：美国糖尿病患病率的不断上升继续推动医疗资源利用率的稳步上升。连续血糖监测 (CGM) 对广大 2 型糖尿病人群住院治疗的实际影响尚不完全清楚。方法：在这项回顾性分析中，我们使用 Optum 超过 7900 万人的去识别市场清晰度数据来评估 74,264 名 2 型糖尿病患者的连续血糖监测 (CGM) 使用情况，这些患者接受非胰岛素治疗 (NIT；n=25,788)、基础胰岛素 (NIT) 治疗。 BIT；n=25,292）和餐时胰岛素治疗（PIT；n=23,184）。主要结局是指数后 6 个月和 12 个月内全因住院率 (ACH)、急性糖尿病相关住院率 (ADH) 和急性糖尿病相关急诊室就诊率 (ADER) 的变化。结果：所有三组的 ACH、ADH 和 ADER 在前 6 个月（指数后）均显着降低：NIT（14%、32%、30%）、BIT（25%、57%、37%）、个人所得税（25%、54%、36%）。 （图 1）NIT（10%、31%、30%）、BIT（23%、56%、34%）和 PIT（19%、49%、36%）持续下降 6-12 个月分别（所有p<0.0001）。结论：在现实世界中，在 2 型糖尿病患者的不同治疗方案中使用 CGM 与全因住院、急性糖尿病相关住院和急诊就诊的显着减少相关。披露Garg：研究支持；礼来公司。顾问小组；美敦力。研究支持；美敦力。顾问小组；诺和诺德。研究支持； DarioHealth Corp.、Dexcom, Inc.、Diasome。顾问小组；罗氏糖尿病护理。 I.B.赫希：顾问小组；雅培。研究支持； Dexcom, Inc. 顾问小组；罗氏糖尿病护理。 研究支持； MannKind Corporation、Tandem Diabetes Care, Inc. 顾问小组；恩贝克塔。研究支持； Tandem Diabetes Care, Inc. 顾问小组；福泰制药公司。 E. Repetto：雇员；罗氏糖尿病护理。 J.K.斯内尔-伯让：没有。 B. 乌尔默：雇员；罗氏糖尿病护理。 C.帕金斯：员工；罗氏糖尿病护理。 R M。 Bergenstal：其他关系；雅培。研究支持；爱科来营销。顾问; Ascensia 糖尿病护理、Bigfoot Biomedical, Inc.、CeQur。其他关系； Dexcom 公司、礼来公司。顾问; embecta，Hygieia。研究支持；英苏莱特公司。顾问;曼金德公司。其他关系；美敦力、诺和诺德。顾问; Onduo LLC，罗氏糖尿病护理。其他关系；赛诺菲。研究支持； Tandem Diabetes Care, Inc. 其他关系；联合健康集团。顾问; Vertex 制药公司、Zealand Pharma A/S。 资助罗氏诊断、糖尿病护理